Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
13 March 2019 | Story Zama Feni | Photo Zama Feni
Career fair
UFS BCom (Marketing) student, Thandokazi Kiviet, who works part time for fellow master’s student Refilwe Xaba’s hair-product company, Glolooks, shows off their products to visitors at the Annual Careers Fair last week.

Budding student entrepreneurs from the University of the Free State presented their creative displays during the first part of the university’s 2019 Annual Careers Fair at the Callie Human Hall last week.

The first leg of the fair was in the Faculty of Economic and Management Sciences, with more than 15 companies exhibiting their products and explaining to students their business operations, career prospects, and employment opportunities.

Students’ construction business gets off the ground

Three ladies, Mannini Setai (master’s in Law), Refilwe Mogole (PhD in Chemistry), and Nthabiseng Molejane (honours in the Humanities) registered their company, Ahang Amalmagate Trading, in 2016 and have been operating since late 2017.

Mogole said they are currently operating from a backyard in Parys, but they have a manager on site who deals with the technical aspects of their business and runs the daily operations. 

“We managed to buy a brick-making machine, which enabled us to make up to 1 000 bricks per day; at this stage, we provide bricks to private homeowners,” she said.

The ladies said winning three competitions last year gave them a financial boost that aided them greatly; these included the Nampak Entrepreneurship Competition, the Free State Department of Economic, Small Business Development, Tourism and Environmental Affairs Tabalaza Pitching Programme, as well as the UFS Directorate for Research Development’s business pitching competition.

“As a result of these competitions, we managed to save some cash to buy ourselves a brick-making machine,” said Setai, adding that they are using social networks to market their product.

Hair-product business gives hope

Another student business stall was that of Glolooks – an emerging hair-products company established by UFS student, Refilwe Xaba, who has just finished her master’s programme in Entrepreneurship at the UFS. “The biggest challenge is access to the markets, but my business is doing fairly well here in Bloemfontein; our use of online media and social networks to market our products is keeping us there,” said Ms Xaba. She said she has just opened an ethnic hair salon in Westdene.

Taking it slowly, but surely

Another UFS student was Anet Matakala of Nettah Organics (Law degree) who makes organic products such as green tea, bath salts, chocolate coffee, cannabis butter, etc., from food-based ingredients. “It’s not an easy road, but step by step, we are getting there,” she said.

The last student was Keagan Nkwaira, who started a clothing company named ‘Weather’ last year. “What drove me to starting this venture was a passion for design and a need to raise cash. Business hasn’t been good so far, but I will have to find marketing initiatives that will get my work to the potential customers,” he said.


Career fairs benefit students

Head of Career Services, Belinda Janeke, said there will be four more career fairs catering for the Faculties of Law and Natural and Agricultural Sciences during the course of the year, and two general career fairs in May and August.

“The career fairs help to connect our students with the world of work, it helps to broaden the horizons for students because they can enquire about the products or services provided by the respective companies, and it can also create job and internship opportunities,” she said.  

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept